基于复合终点的纵向临床试验设计:样本量、监测与适应性设计
本文针对使用Finkelstein-Schoenfeld(FS)检验或胜率(win ratio)作为复合终点分析方法的纵向临床试验,提供设计指导,涵盖样本量计算、序贯监测和适应性设计三个关键问题。文章基于作者此前提出的非参数FS检验及Pocock等提出的胜率估计方法展开论述。
要点
- 使用FS检验或胜率的纵向临床试验设计需考虑样本量、序贯监测与适应性设计。
- FS检验是基于多终点复合的非参数检验方法。
- 胜率汇总了试验组中结局更好与更差患者数量的比值。
核心结论
- 本文旨在为使用FS检验或胜率的试验设计提供指导,涉及样本量、序贯监测和适应性设计。
研究设计与样本
- 本文为方法学指导文章,基于作者此前提出的Finkelstein-Schoenfeld(FS)非参数检验(Finkelstein和Schoenfeld,Stat Med,1999年;18(11):1341-1354)及Pocock等提出的基于多终点的疗效比较估计(胜率,Eur Heart J,2011年;33(2):176-182)展开论述。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Longitudinal clinical trials are often designed to compare treatments on the basis of multiple outcomes. For example in the case of cardiac trials, the outcomes of interest include mortality as well as cardiac events and hospitalization. For a COVID-19 trial, the outcomes of interest include mortality, time on ventilator, and time in hospital. Earlier work by these authors proposed a non-parametric test based on a composite of multiple endpoints referred to as the Finkelstein-Schoenfeld (FS) test (Finkelstein and Schoenfeld. Stat Med. 1999;18(11):1341-1354.). More recently, an estimate of the treatment comparison based on multiple endpoints (related to the FS test) was proposed (Pocock et al. Eur Heart J. 2011;33(2):176-182.). This estimate, which summarized the ratio of the number of patients who fared better vs worse on the experimental arm was coined the win ratio. The aim of this article is to provide guidance in the design of a trial that will use the FS test or the win ratio. The issues that will be considered are the sample size, sequential monitoring, and adaptive designs.
引用
- Schoenfeld DA, Ramchandani R, Finkelstein DM, et al. Designing a longitudinal clinical trial based on a composite endpoint: Sample size, monitoring, and adaptation. Stat Med. 2022. PMID: 35818331. doi:10.1002/sim.9416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。